Differential sensitivity of basal and acetylcholine-induced activity of nitric oxide to blockade by asymmetric dimethylarginine (ADMA) in the rat aorta by AL-Zobaidy, M.J. et al.
 
 
 
 
 
 
 
AL-Zobaidy, M.J., Craig, J. and Martin, W. (2010) Differential sensitivity 
of basal and acetylcholine-induced activity of nitric oxide to blockade by 
asymmetric dimethylarginine (ADMA) in the rat aorta. British Journal of 
Pharmacology, 160 (6). pp. 1476-1483. ISSN 0007-1188 
 
http://eprints.gla.ac.uk/34433/ 
 
Deposited on: 06 August 2010 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
 Differential sensitivity of basal and acetylcholine-induced activity of nitric oxide 
to blockade by asymmetric dimethylarginine (ADMA) in the rat aorta 
 
Mohammed J. AL-Zobaidy, John Craig & *William Martin 
 
Integrative & Systems Biology, Faculty of Biomedical & Life Sciences, West 
Medical Building, University of Glasgow, Glasgow, G12 8QQ, Scotland, UK.  
 
*Corresponding author  
Tel: +44 (0)141 330 4489 
Fax: +44 (0)141 330 5481 
Email: W.Martin@bio.gla.ac.uk 
 
Running title: ADMA and NO 
 
 
Key Words: acetylcholine; ADMA; asymmetric dimethylarginine; endothelium; 
nitric oxide; NOS inhibitor; SDMA; symmetric dimethylarginine; vasodilatation. 
Summary 
Background and purpose: Previous work has shown that NG-monomethyl-L-
arginine (L-NMMA) paradoxically inhibits basal but not acetylcholine-stimulated 
activity of nitric oxide in rat aorta. The aim of this study was to determine if the 
endogenously produced agent, asymmetric NG, NG-dimethyl-L-arginine (ADMA), 
also exhibits this unusual selective blocking action. 
Experimental approach: The effect of ADMA on basal nitric oxide activity was 
assessed by examining its ability to enhance phenylephrine-induced tone in 
endothelium-containing rings. Its effect on acetylcholine-induced relaxation was 
assessed both in conditions where ADMA greatly enhanced phenylephrine tone and 
where tone was carefully matched with control tissues at a range of different levels. 
Key results: ADMA (100 μM) potentiated phenylephrine-induced contraction, 
consistent with inhibition of basal nitric oxide activity. Higher concentrations (300-
1000 μM) had no greater effect. Although ADMA (100 μM) also appeared to block 
acetylcholine-induced relaxation when it enhanced phenylephrine tone to maximal 
levels, virtually no block was seen at intermediate levels of tone in the presence of 
ADMA. Even ADMA at 1000 μM had no effect on the maximal relaxation to 
acetylcholine, although it produced a small (2-3-fold) reduction in sensitivity. ADMA 
and L-NMMA, like L-arginine (all at 1000 μM), protected acetylcholine-induced 
relaxation against blockade by L-NAME (30 μM). 
Conclusions and implications: In the rat aorta, ADMA, like L-NMMA, blocks basal 
activity of nitric oxide but has little effect on that stimulated by acetylcholine. Further 
studies are required to explain these seemingly anomalous actions of ADMA and L-
NMMA. 
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 Abbreviations: ADMA, asymmetric NG, NG-dimethyl-L-arginine; L-NAME, NG-
nitro-L-arginine methyl ester; L-NMMA, NG-monomethyl-L-arginine; NOS, nitric 
oxide synthase; SDMA, symmetric NG, N’G-dimethyl-L-arginine. 
 
Introduction 
 
It is well established that one of the two equivalent guanidino nitrogens of L-arginine 
is utilised by nitric oxide synthase (NOS) in the synthesis of nitric oxide (Palmer et 
al., 1988).  Since this discovery, an extensive range of guanidino (NG)-substituted 
analogues of L-arginine have been developed as inhibitors of NOS (Rees et al., 1989; 
Moore et al., 1990; Rees et al., 1990; Hobbs et al., 1999) and these have become 
valuable tools for investigating the role of the L-arginine-nitric oxide system in 
biological processes. Amongst the earliest examples developed were NG-
monomethyl-L-arginine (L-NMMA), NG-nitro-L-arginine (L-NOARG) and NG-nitro-
L-arginine methyl ester (L-NAME). These remain the most commonly used 
investigational tools in experimental biology, probably because they are effective 
blockers of all three isoforms of NOS, i.e. the endothelial (eNOS), neuronal (nNOS) 
and inducible (iNOS) forms. In the vast majority of cases, these three agents are not 
metabolised by NOS, but act as classical competitive inhibitors, whose actions can be 
either prevented or reversed by an excess of the substrate, L-arginine. Of these three 
agents, however, L-NMMA alone has frequently been reported to exhibit properties 
that are inconsistent with it acting as a simple competitive inhibitor. For example, L-
NMMA acts as an alternative substrate and mechanism-based suicide inhibitor of 
iNOS in murine macrophages (Olken & Marletta, 1993). Furthermore, unlike L-
NOARG and L-NAME, L-NMMA fails to inhibit nitrergic nerve (nNOS) mediated 
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relaxation in the bovine penile and ciliary arteries and retractor penis muscle (Liu et 
al., 1991; Martin et al., 1993; Overend & Martin, 2007). Most surprisingly of all, 
however, is that L-NMMA selectively blocks basal but not agonist (acetylcholine or 
ATP)-induced activity of nitric oxide in rat aorta (Frew et al., 1993). Furthermore, this 
study showed that pretreatment with L-NMMA protects agonist-induced nitric oxide 
activity against blockade by L-NOARG in a manner similar to L-arginine, suggesting 
it might act as an alternative substrate for eNOS. Indeed, chemiluminescence 
detection has confirmed that L-NMMA, like L-arginine, but unlike L-NOARG, can 
fuel nitric oxide synthesis in rat aorta and pulmonary artery (Archer & Hampl, 1992).  
 
Renewed interest in the biological actions of methylarginines was sparked by the 
discovery that L-NMMA, asymmetric NG, NG-dimethyl-L-arginine (ADMA) and 
symmetric NG, N’G-dimethyl-L-arginine (SDMA) are produced endogenously during 
the proteolytic digestion of methylated proteins (Vallance et al., 1992; Leiper & 
Vallance, 2006). These authors showed also that ADMA, like L-NMMA, inhibits 
NOS but SDMA does not. Moreover, while the plasma concentration of L-NMMA is 
low, levels of ADMA and SDMA are around 10-times higher and accumulate further 
in renal failure (Vallance et al., 1992) and a wide range of pathological conditions 
associated with vascular dysfunction, including hypertension, pulmonary 
hypertension, atherosclerosis, diabetes mellitus and preeclampsia  (Siroen et al., 2006; 
Leiper & Vallance, 2006).  
 
In view of the growing evidence for the involvement of ADMA in cardiovascular 
disease, the aim of this study was to determine if this agent shared with L-NMMA the 
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ability to block selectively basal but not acetylcholine-stimulated activity of nitric 
oxide in rat aorta. 
 
Methods 
Preparation of aortic rings and tension recording 
The preparation of rat aortic rings for tension recording was essentially similar to a 
previous study (Frew et al., 1993). Briefly, female Wistar rats weighing 150-200 g 
were killed by stunning and exsanguination. The aorta was removed, cleared of 
adhering fat and connective tissue and cut into 2.5 mm wide transverse rings using a 
device with parallel razor blades. Endothelial cells were removed from some rings by 
gently rubbing the intimal surface with a moist wooden stick for 30 s. Successful 
removal of the endothelium was confirmed by the inability of acetylcholine (1 μM) to 
elicit relaxation. The aortic rings were mounted under 10 mN resting tension on 
stainless steel hooks in 10 ml tissue baths, and bathed at 37 °C in Krebs solution 
containing (mM): NaCl 118, KCl 4.8, CaCl2 2.5, MgSO4 1.2, KH2PO4 1.2, NaHCO3 
24, glucose 11, and gassed with 95 % O2 and 5 % CO2. Tension was recorded 
isometrically with Grass FTO3C transducers and displayed on a PowerLab 
(ADInstruments, Hastings, UK). 
 
Experimental protocols with the rat aorta 
The ability of ADMA to block basal activity of nitric oxide was assessed from its 
enhancement of agonist-induced contraction in endothelium-containing aortic rings 
(Frew et al., 1993). This was performed in two ways. The first, by obtaining a low-
level contraction (~2-5 mN) to phenylephrine (30-60 nM) and then measuring the 
enhancement of tone produced by a range of ADMA concentrations (0.3-300 μM), 
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each for 1 h. The ability of L-arginine (10 mM, 1 h) to either protect against or 
reverse the enhancement by ADMA (100 μM) was also assessed. The effects of 
ADMA were also examined on phenylephrine-induced tone in endothelium-denuded 
rings. We also determine if submaximal tone induced by 5-hydroxytryptamine (3 μM) 
or by prostaglandin F2α (3 μM) in endothelium-containing rings was enhanced when 
subsequently treated with ADMA (100 μM). The second protocol for examining 
blockade of basal nitric oxide activity involved pretreating endothelium-containing 
rings for 1 h with ADMA (100, 300 or 1000 μM) and then constructing full 
concentration-response curves to phenylephrine (1 nM-10 μM), together with time-
matched controls.  
 
Agonist-stimulated activity of nitric oxide was assessed by measuring the relaxation 
to acetylcholine (1 nM-10 μM) in endothelium-containing rings. When the effects of 
ADMA or other NOS inhibitors were to be examined, they were added for 1 h before 
construction of the acetylcholine concentration-response curve. As will be seen in the 
Results, the level of phenylephrine tone was critical in determining the magnitude of 
acetylcholine-induced relaxation both in control and ADMA-treated tissues. In some 
experiments with ADMA, its effects on relaxation were examined after it had 
enhanced phenylephrine-induced tone, whereas in others, the tone was carefully 
matched with those of control tissues at low, intermediate or maximal levels. In other 
experiments, the ability of ADMA (100 μM) to affect acetylcholine-induced 
relaxation was also assessed on sub-maximal tone induced by 5-hydroxytryptamine or 
prostaglandin F2α. 
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In some experiments, L-NAME (30 μM, 1h) was used to inhibit maximal 
acetylcholine (1 nM-10 μM)-induced relaxation by ~ 50 %. In these, the ability of L-
arginine, L-NMMA, ADMA or SDMA (all at 1000 μM; pre-treatment or post-
treatment for 1h) either to protect against or reverse this inhibition by L-NAME was 
also assessed.  
 
Drugs and chemicals 
Acetylcholine chloride, ADMA (asymmetric NG, NG-dimethyl-L-arginine 
dihydrochloride), L-arginine hydrochloride, 5-hydroxytryptamine, L-NAME (NG-
nitro-L-arginine methyl ester), L-NMMA (NG-monomethyl-L-arginine acetate), 
papaverine hydrochloride, phenylephrine hydrochloride and prostaglandin F2α were 
all obtained from Sigma, UK. SDMA (symmetric NG, N’G-dimethyl-L-arginine 
dihydrochloride) was obtained from Enzo Life Sciences, UK. All drugs were 
dissolved and diluted in 0.9% saline.  
 
Data analysis 
Contractions were measured in milliNewtons. Papaverine (300 μM) was added at the 
end of each experiment to fully relax tissues, and acetylcholine-induced relaxations 
were calculated as % relaxation of phenylephrine-induced tone with respect to this 
baseline. Data are expressed as the mean ± s.e.mean of n separate observations, each 
from a separate tissue. Graphs were drawn and statistical comparisons made using 
one-way analysis of variance and Bonferroni’s post-test with the aid of a computer 
program, Prism (GraphPad, San Diego, USA). A probability (P) less than or equal to 
0.05 was considered significant. 
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Results 
Effects of ADMA on basal nitric oxide activity  
Following induction of a low level of contraction (3.1 ± 0.6 mN) of endothelium-
containing rings of rat aorta using phenylephrine (30-60 nM), subsequent addition of 
ADMA (0.3-300 μM) led to an immediate further elevation of tone, consistent with 
inhibition of basal nitric oxide activity (Figure 1 and Figure 2b). The threshold 
concentration was 0.3-1 μM and the maximum was obtained at 100 μM. The 
enhancement of phenylephrine-induced contraction by ADMA (100 μM) was both 
prevented and reversed by treatment with L-arginine (10 mM). ADMA did not 
enhance phenylephrine-induced contraction in endothelium-denuded rings. In contrast 
to ADMA, SDMA (100 μM) had no effect on phenylephrine-induced contraction in 
endothelium-containing rings. Sub-maximal contraction induced by 5-
hydroxytryptamine (3 μM) or prostaglandin F2α (3 μM) was also enhanced by ADMA 
(100 μM).  
 
A full concentration-response curve to phenylephrine (1 nM-10 μM) in endothelium-
containing rings gave an Emax of 14.4 ± 1.5 mN and a pEC50 of 6.75  ± 0.07 (Figure 
2). Pretreatment with ADMA (100 μM) for 1 h enhanced both the Emax (22.2 ± 0.8 
mN) and sensitivity (pEC50 7.88 ± 0.04) to phenylephrine. Increasing the 
concentration of ADMA to 300 or 1000 μM produced little additional enhancement. 
 
Effects of ADMA on acetylcholine-induced relaxation 
Following induction of intermediate phenylephrine-induced tone (11.9 ± 2.1 mN) on 
endothelium-containing rings, acetylcholine (1 nM-10 μM) produced concentration-
dependent relaxation (Emax 77.5 ± 7.8 %; pEC50 7.30 ± 0.03; Figure 3a and b). When 
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ADMA (100 μM, 1 h) was added on top of this intermediate phenylephrine-induced 
contraction, raising tone to a higher level (18.8 ± 1.5 mN), acetylcholine-induced 
relaxation was depressed (Emax 22.1 ± 3.1 %; pEC50 6.91 ± 0.04). However, when 
these same tissues were washed, with restoration of intermediate phenylephrine-
induced tone (7.6 ± 0.9 mN) in the presence of ADMA, the blockade of acetylcholine-
induced relaxation was almost completely abolished: maximal relaxation was similar 
to controls, but there was a 1.7-fold reduction in sensitivity (Emax 77.6 ± 4.0 %; pEC50 
7.06 ± 0.04). Concentrations of ADMA below 100 μM at sub-maximal 
phenylephrine-induced tone had no effect on acetylcholine-induced relaxation. 
ADMA (100 μM) at intermediate levels of tone induced by 5-hydroxytryptamine or 
prostaglandin F2α also failed to affect maximal acetylcholine-induced relaxation, but 
produced modest reductions in sensitivity of 2.6- and 2.3-fold (data not shown). 
 
These findings prompted us to examine the effect the level of tone had on the 
magnitude of acetylcholine induced relaxation in control and ADMA (100 μM)-
treated rings. In control rings, acetylcholine (1 nM-10 μM)-induced relaxation was 
similar at two different levels of submaximal phenylephrine-induced tone (3.7 ± 0.4 
and 10.3 ± 0.5 mN; Figure 4a). Relaxation was, however, significantly depressed at a 
maximal level of tone (14.1 ± 0.5 mN). The ability of ADMA (100 μM) to enhance 
phenylephrine-induced contraction permitted examination of a wider range of tone 
levels in the presence of this agent. At levels of phenylephrine-induced tone of 4.1 ± 
0.6 or 10.2 ± 0.5 mN in the presence of ADMA, maximal acetylcholine-induced 
relaxation was not significantly different from controls at similar levels of tone 
(Figure 4a and b). However at 15.7 ± 0.5 mN tone, acetylcholine-induced relaxation 
was depressed, but to the same extent as control tissues at the same level of tone. At 
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20.3 ± 0.7 mN and 24.7 ± 0.6 mN tone, which cannot be achieved in control tissues, 
acetylcholine-induced relaxation was even more depressed. 
 
With a higher concentration of ADMA (1000 μM, 1 hr) at intermediate 
phenylephrine-induced tone, the Emax to acetylcholine was unaffected, but there was a 
2.0-fold decrease in sensitivity when compared to controls (Figure 5; Table 1). 
Testing these tissues again at 3 h and 4.5 h showed a slight progressive decrease in 
sensitivity to acetylcholine in controls, but in ADMA-treated tissue the Emax remained 
unchanged when compared to time-matched controls, with a roughly similar decrease 
in sensitivity (3-fold) to that seen at 1 h.   
 
Effects of ADMA on the blockade of acetylcholine-induced relaxation by L-NAME 
In the presence of intermediate phenylephrine-induced tone, L-NAME (30 μM, 1 h) 
blocked maximal acetylcholine (1 nM-10 μM)-induced relaxation by ~50 % (Figure 
6). This blockade was both largely prevented and reversed by treatment with L-
arginine (1000 μM; Figure 6a). L-NMMA (1000 μM) induced a 2.6-fold reduction in 
sensitivity to acetylcholine without affecting the Emax and, like L-arginine, both 
prevented and reversed the blockade induced by L-NAME (Figure 6b; Table 1). 
ADMA (1000 μM) too produced significant protection but did not reverse the 
blockade induced by L-NAME (Figure 6c). SDMA (1000 μM) had no effect by itself 
on acetylcholine-induced relaxation and did not prevent or reverse the blockade 
induced by L-NAME (Figure 6d; Table 1). 
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Discussion 
The main new finding in this study is that while ADMA blocks basal activity of nitric 
oxide in rat aorta, it has little effect on that stimulated by acetylcholine. These 
seemingly anomalous findings parallel the actions of L-NMMA in rat aorta (Frew et 
al., 1993), but are in stark contrast to those of L-NOARG and L-NAME which, as 
expected of typical NOS inhibitors, uniformly abolish both basal and agonist 
(acetylcholine or ATP)-stimulated activity of nitric oxide. 
 
Basal nitric oxide activity exerts a tonic endothelium-dependent vasodilator influence 
in many isolated blood vessels and is typically assessed by observing the rise in 
submaximal vasoconstrictor-induced tone produced by agents that inhibit either the 
action or synthesis of nitric oxide (Martin et al., 1986; Rees et al., 1989; Moore et al., 
1990). These authors, working on rat and rabbit aorta and rat mesentery concluded 
that this basal vasodilator influence opposing vasoconstriction resulted from the 
spontaneous (i.e. unstimulated) release of nitric oxide from the endothelium. In these 
tissues there was no evidence that the constricting adrenoceptor agonists used had 
stimulated release of nitric oxide through activation of endothelial α2-adrenoceptors 
as occurs in canine and porcine coronary and pulmonary arteries (Cocks & Angus, 
1983; Miller & Vanhoutte, 1985). Others, have instead suggested that vascular 
smooth muscle contraction may indirectly stimulate endothelial cells to release nitric 
oxide via a signal transmitted either through myoendothelial gap junctions (Jackson et 
al., 2008; Dora et al., 2000) or by mechanical stress (Fleming et al., 1999). However, 
in endothelium-containing untreated rings of rat aorta, cyclic GMP levels are 2-3-fold 
higher than in endothelium-denuded rings (Rapoport & Murad, 1983), thus 
demonstrating that the tonic influence of basal nitric oxide is present in the complete 
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absence of smooth muscle activation. Nevertheless, regardless of the mechanisms 
governing the basal activity of nitric oxide, there is general agreement that NOS 
inhibitors enhance vasoconstrictor tone by abolishing its inhibitory influence. In 
keeping with a previous report (Vallance et al., 1992), we found that the 
endogenously produced NOS inhibitor, ADMA, also enhances vasoconstrictor tone 
induced by a number of agents (phenylephrine, 5-hydroxytryptamine or prostaglandin 
F2α) in rat aorta. Both studies report a threshold effect for ADMA at 0.3-1 μM, 
consistent with concentrations found in the plasma in a number of disease states 
(Vallance et al., 1992; Siroen et al., 2006), and a maximal effect at ~100 μM. They 
also show that the inactive isomer, SDMA, lacks the ability of ADMA to enhance 
vasoconstrictor tone. Moreover, the ability of the endogenous substrate, L-arginine, to 
both protect against and reverse blockade of basal nitric oxide activity by ADMA 
shows it occurs by simple competitive antagonism. 
 
Our most striking new finding is that ADMA, at a concentration of 100 μM which 
abolishes basal nitric oxide activity, has virtually no effect on acetylcholine-induced 
relaxation. Although ADMA appeared to produce blockade under conditions where it 
had potentiated phenylephrine-induced tone to near maximal levels, this was almost 
certainly due to physiological antagonism rather than blockade of NOS, since 
matching this increased tone in control tissues with additional phenylephrine 
produced a similar degree of blockade. When phenyleprine-induced tone in the 
presence of ADMA was held at intermediate levels, virtually no blockade of 
acetylcholine-induced relaxation was seen; there was a modest 1.7-fold reduction in 
sensitivity without any effect on the maximal relaxation. ADMA was similarly 
ineffective against acetylcholine-induced-relaxation in tissues contracted 
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submaximally with 5-hydroxytryptamine or prostaglandin F2α. Even increasing both 
the concentration of ADMA to 1000 μM and the time of exposure to 4.5 h at 
intermediate levels of phenylephrine tone failed to produce any greater blockade of 
acetylcholine-induced relaxation. These findings are clearly in conflict with previous 
studies on rat aorta which report blockade of acetylcholine-induced relaxation by 
ADMA (Vallance et al., 1992; Jin & D'Alecy, 1996; Feng et al., 1998). Since these 
authors made no mention of matching the tone in control and ADMA-treated tissues, 
it is likely that the blockade of acetylcholine-induced relaxation they reported resulted 
from physiological antagonism, due to over-contraction, rather than to blockade of 
NOS. 
 
Our finding that ADMA blocks basal but not acetylcholine-induced nitric oxide 
activity in rat aorta mirrors what we reported previously for L-NMMA (Frew et al., 
1993). Furthermore, just like the endogenous substrate, L-arginine, both ADMA and 
L-NMMA, protect acetylcholine-induced relaxation against blockade by the NOS 
inhibitor, L-NAME; L-arginine and L-NMMA also reversed established blockade by 
L-NAME, but ADMA failed to do this after an hour of treatment, perhaps due to 
lower potency than the other agents. Whether or not longer treatments with ADMA 
would have reversed the blockade by L-NAME was not investigated. Thus, although 
ADMA and L-NMMA both act like conventional competitive inhibitors of basal nitric 
oxide synthesis, they paradoxically appear to behave more like substrates for 
acetylcholine-induced and ATP-induced (Frew et al., 1993) synthesis of nitric oxide. 
Indeed, chemiluminescence detection has revealed that L-NMMA, just like L-
arginine, fuels the synthesis of nitric oxide in rat aorta and pulmonary artery, whereas 
L-NOARG inhibits it (Archer & Hampl, 1992). It is unlikely that demethylation 
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reactions to form L-arginine explains the abilities of ADMA and L-NMMA to behave 
as alternative substrates for agonist-stimulated eNOS, because the blockade they 
produce of basal NO activity is sustained, suggestive of on-going stability of these 
agents.  
 
At present we can only speculate about the mechanisms that govern why ADMA and 
L-NMMA block basal but have little effect on agonist-stimulated activity of nitric 
oxide. It is possible that different isoforms of eNOS, with different structural 
requirements for substrates and inhibitors, might be responsible for basal and agonist-
stimulated production of nitric oxide, but there is no evidence in the literature to 
support this. Alternatively, it is known that activation of eNOS by acetylcholine or 
ATP via Ca2+-calmodulin binding induces a conformational change that permits 
dissociation of the enzyme from its inhibitory anchor protein, caveolin-1 (Dudzinski 
& Michel, 2007). It is therefore possible that a concomitant conformational change in 
the eNOS substrate binding site occurs such that it now recognises ADMA and L-
NMMA as substrates rather than inhibitors. In this context, there is good evidence that 
flow-mediated dilatation, which occurs through the Ca2+-independent activation of 
eNOS via phosphorylation by the phosphatidylinositol 3-kinase/Akt pathway (Fulton 
et al., 1999; Gallis et al., 1999), is inhibited by ADMA in humans (Boger et al., 1998; 
Vladimirova-Kitova et al., 2008).  A direct comparison of the differential sensitivity 
to blockade by ADMA and L-NMMA of stimuli operating via Ca2+-calmodulin-
stimulated and phosphorylation-stimulated activation of eNOS in a single tissue will 
be required to explore this more thoroughly. 
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Although ADMA and L-NMMA block basal but not agonist-induced activity of nitric 
oxide in rat aorta, both elevate blood pressure when infused into anaesthetised rats 
(Rees et al., 1990; Jin & D'Alecy, 1996; De Gennaro Colonna et al., 2007). It would 
therefore be interesting to explore in vivo the sensitivity to blockade by ADMA and 
L-NAME of the components of nitric oxide activity (basal vs flow-stimulated vs 
agonist-stimulated) that contribute to the regulation of blood pressure. Indeed, since 
ADMA and L-NMMA both elevate vascular tone in human volunteers (Vallance et 
al., 1989; Vallance et al., 1992) and the former accumulates in a number of disease 
states (Vallance et al., 1992; Siroen et al., 2006; Leiper & Vallance, 2006), it will be 
valuable to re-assess the effects of ADMA and L-NMMA on isolated blood vessels 
from a range of species, including humans, to determine if the differential sensitivity 
of basal and agonist-stimulated activity of nitric oxide seen in the rat occurs 
elsewhere. We would caution that such studies should be conducted at submaximal 
tone with matched controls to ensure the outcomes are not compromised by 
physiological antagonism, resulting from over-contraction of inhibitor-treated tissues. 
 
In conclusion, our findings demonstrate that ADMA, like L-NMMA, preferentially 
blocks basal activity of nitric oxide in rat aorta, but has little effect on that stimulated 
by acetylcholine. Previous reports suggesting blockade of acetylcholine-induced 
relaxation of this tissue by ADMA are likely to have been due to physiological 
antagonism rather than blockade of NOS. Further studies will be required to 
determine the mechanism by which ADMA and L-NMMA produce this paradoxically 
selective action. 
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Figure Legends 
Figure 1. ADMA (100 μM) enhances tone induced by phenylephrine (PE), 5-
hydroxytryptamine (5-HT) or prostaglandin F2α (F2α) in endothelium-containing but 
not endothelium-denuded (-EC) rings of rat aorta. The enhancement of PE-induced 
tone is both prevented and reversed by treatment with L-arginine (10 mM). In contrast 
to ADMA, SDMA (100 μM) does not enhance tone in endothelium-containing rings. 
In the trace (a) concentrations are given in log molar units. In the histogram (b) the 
order of listing of drugs (PE, ADMA, L-arg; L-arg, PE, ADMA etc) reflects their 
order of addition to tissues; data are the mean ± s.e.mean of 6 observations. *** 
P<0.001 indicates a significant enhancement by ADMA; ### P<0.001 indicates a 
significant difference in the presence of L-arginine. 
 
Figure 2. (a) Concentration-response curves showing the contractile effects of 
phenylephrine (PE) on endothelium-containing rings of rat aorta and the enhancement 
of this tone following pretreatment for 1 h with ADMA (100, 300 and 1000 μM). (b) 
Concentration-response curve showing the ability of ADMA to enhance low level 
contraction to phenylephrine (30-60 nM); the response to each concentration of 
ADMA was measured after 1h. Each point is the mean ± s.e.mean of 6-15 
observations. *** P<0.001 indicates a significant difference from control. 
 
Figure 3. Experimental traces (a) and concentration-response curves (b) showing that 
when ADMA (100 μM, 1 h) enhances phenylephrine (PE, 0.1-0.3 μM)-induced tone 
to a high (H) level, acetylcholine (Ach)-induced relaxation appears powerfully 
inhibited. However, when these same tissues are washed, with intermediate PE (10-30 
nM)-induced tone (I) re-established in the presence of ADMA, the blockade of 
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acetylcholine-induced relaxation is almost entirely abolished. Each point is the mean 
± s.e.mean of 6 observations. *** P<0.001 indicates a significant difference from 
control. 
 
Figure 4. Concentration-response curves showing acetylcholine (Ach)-induced 
relaxation in aortic rings taken to different levels of phenylephrine tone (indicated in 
mN) in (a) control tissues and (b) in tissues treated with ADMA (100 μM, 1 h). Both 
control and ADMA treated tissues exhibit depression of relaxation but only at high 
levels of tone. Each point is the mean ± s.e.mean of 6-9 observations. * P<0.05, ** 
P<0.01 and *** P<0.001 indicate significant differences from the first control. 
 
Figure 5. Concentration-response curves showing acetylcholine (Ach)-induced 
relaxation at intermediate phenylephrine tone in control tissues (Control 1) and tissues 
treated with ADMA (1000 μM) for 1 hr (ADMA 1). These same tissue were tested 
again at 3h (Control 2; ADMA 2) and at 4.5 h (Control 3; ADMA 3), but there was 
little evidence of progressive blockade with time using ADMA. Each point is the 
mean ± s.e. mean of 5-6 observations. 
 
Figure 6. Concentration-response curves showing acetylcholine (Ach)-induced 
relaxation at intermediate phenylephrine tone and blockade of this relaxation with L-
NAME (30 μM, 1 h). The ability of (a) L-arginine, (b) L-NMMA, (c) ADMA and (d) 
SDMA (all at 1000 μM) to either protect against or reverse blockade by L-NAME is 
also shown. Note that the order of listing of drugs reflects their order of addition to 
tissues. Each point is the mean ± s.e.mean of 6-9 observations. *** P<0.001 indicates 
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significant blockade by L-NAME; ## P<0.001 and ### P<0.001 indicate significant 
protection against or reversal of blockade induced by L-NAME. 
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Table 1. Effects of NOS inhibitors on acetylcholine-induced relaxation of rat aorta, 
together with time-matched controls. All experiments were conducted at submaximal 
levels of phenylephrine-induced tone.       
 
Treatment Concentration  Emax (%)  pEC50 
 
Control -   81.3 ± 5.9  7.61 ± 0.02 
ADMA 1000 μM (1 h)  83.8 ± 2.8  7.31 ± 0.07 **  
 
Control -   87.9 ±2.5  7.33 ± 0.04 # # 
ADMA 1000 μM (4.5 h) 81.9 ± 2.3  6.85 ± 0.04 *** 
 
Control -   93.3 ±2.8   7.51 ± 0.03 
SDMA  1000 μM (1 h)  91.2 ± 4.4  7.52 ± 0.04 
 
Control -   86.0 ± 5.8  7.54 ± 0.05 
L-NMMA 1000 μM (1 h)  89.0 ± 4.3  7.12 ± 0.04 ***  
Data are expressed at mean ± s.e.mean of n=6-9 observations. ** P<0.01 and *** 
P<0.001 indicate significant differences from respective controls. # # P<0.01 indicates 
a difference from the control at 1 h. 
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